GlaxoSmithkline, Sanofi-Aventis, and Wyeth feel the pharmaceutical hurt as stocks continue to drop and FDA regulations continue to tighten. Investors are also facing confusion as FDA has begun to share preliminary drug information with the general public.
"The FDA has been under incredible pressure and its creating a bit of a straight-jacket for product development, Jeremy Batstone, an analyst at Charles Stanley said in an interview."
For the full story, click here.
MV
